ReviewMethods in molecular biology (Clifton, N.J.)2012
Neisseria meningitidis: biology, microbiology, and epidemiology.
Review in Methods in molecular biology (Clifton, N.J.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01766206 (A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline), which is not on this map. Cited by 199 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea.
Who cites it
199 citing papers in PubMed, 7 syntheses or guidelines pooled it, 416 citations in OpenAlex.
- Global epidemiology of serogroup Y invasive meningococcal disease: a literature review.Epidemiology and infection · 2024Pooled it
- Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region.BMC infectious diseases · 2021Pooled it
- A meta-analytic evaluation of sex differences in meningococcal disease incidence rates in 10 countries.Epidemiology and infection · 2020Pooled it
- Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review.Journal of global health · 2019Pooled it
- Meningococcal serogroups and surveillance: a systematic review and survey.Journal of global health · 2019Pooled it
- Pre-admission antibiotics for suspected cases of meningococcal disease.The Cochrane database of systematic reviews · 2017Pooled it
- Carriage prevalence of Neisseria meningitidis in the Americas in the 21st century: a systematic review.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesPooled it
- Safety and immunogenicity of a 3-dose schedule of a quadrivalent meningococcal tetanus toxoid conjugate vaccine administered concomitantly with routine pediatric vaccines to infants and toddlers: A descriptive randomized study.Human vaccines & immunotherapeutics · 2025Trial
- Social and behavioral predictors of two-doses 4CMenB vaccine series among adolescents enrolled in a cluster randomized controlled trial in Australia.Human vaccines & immunotherapeutics · 2022Trial
- Safety and immunogenicity of meningococcal (Groups A and C) polysaccharide vaccine in children 2 to 6 y of age in China: a randomized, active-controlled, non-inferiority study.Human vaccines & immunotherapeutics · 2021Trial
- Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine.Molecular systems biology · 2020Trial
- Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study.Human vaccines & immunotherapeutics · 2020Trial
- Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.Human vaccines & immunotherapeutics · 2020Trial
- Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study.Human vaccines & immunotherapeutics · 2020Trial
- Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.Human vaccines & immunotherapeutics · 2015Trial
- Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.Clinical and vaccine immunology : CVI · 2013Trial
- Parental knowledge, attitudes, and acceptability of meningococcal vaccination in Istanbul, Turkey: A cross-sectional survey.Human vaccines & immunotherapeutics · 2026Article
- Meningococcal vaccination counts and public attention: A time-series study from Türkiye.Human vaccines & immunotherapeutics · 2026Article
- Isolation ofMicroorganisms · 2026Article
- Management and clinical outcomes of meningococcal disease in pediatric and adolescent patients in Makkah, Saudi Arabia: A retrospective bicenter study.IJID regions · 2026Article
139 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Neisseria meningitidis (the meningococcus) causes significant morbidity and mortality in children and young adults worldwide through epidemic or sporadic meningitis and/or septicemia. In this review, we describe the biology, microbiology, and epidemiology of this exclusive human pathogen. N.meningitidis is a fastidious, encapsulated, aerobic gram-negative diplococcus. Colonies are positive by the oxidase test and most strains utilize maltose. The phenotypic classification of meningococci, based on structural differences in capsular polysaccharide, lipooligosaccharide (LOS) and outer membrane proteins, is now complemented by genome sequence typing (ST). The epidemiological profile of N. meningitidis is variable in different populations and over time and virulence of the meningococcus is based on a transformable/plastic genome and expression of certain capsular polysaccharides (serogroups A, B, C, W-135, Y and X) and non-capsular antigens. N. meningitidis colonizes mucosal surfaces using a multifactorial process involving pili, twitching motility, LOS, opacity associated, and other surface proteins. Certain clonal groups have an increased capacity to gain access to the blood, evade innate immune responses, multiply, and cause systemic disease. Although new vaccines hold great promise, meningococcal infection continues to be reported in both developed and developing countries, where universal vaccine coverage is absent and antibiotic resistance increasingly more common.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.